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Treatment Comparison using the Bayesian approach. Nevertheless, for each of these 
methods there are speciﬁ c assumptions which have to be satisﬁ ed in order to obtain 
correct estimation. 
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Study Design
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OBJECTIVES: Conference searching is a common part of systematic review methodol-
ogy, this study investigates what proportion of study/trial data included in systematic 
reviews of pharmacologic interventions is derived solely from data published in confer-
ence abstracts, for 3 different disease areas. METHODS: The Cochrane Library of 
systematic reviews (SRs) was searched for SRs on pharmacologic interventions which 
state that they include conference abstracts in their Specialized Registers and include 
conference searching as part of the stated SR methods. Included studies lists of com-
pleted systematic reviews were reviewed and the total number of included studies and 
the number of studies for which data was obtained only from conference abstracts 
were extracted. In disease areas where a large number of SRs met the inclusion criteria, 
the 10 most recently published SRs were selected. The following disease groups were 
considered: psychological disease (depression and bipolar disorder), female cancers 
(breast cancer and ovarian cancer), and arthritis (osteoarthritis and rheumatoid arthri-
tis). RESULTS: 3/10, 9/10 and 4/10 SRs contained studies solely from conference 
abstracts, for psychological disease, female cancers and arthritis respectively. For psy-
chological disease 5% (5/226) of all studies included in 10 SRs came only from confer-
ence abstracts, for female cancers this was 14% (31/220) and for arthritis this was 14% 
(33/232). CONCLUSIONS: The proportion of studies from conference abstracts only 
included in SRs varies in the 3 examined disease areas. From these results, there is 
some evidence to suggest that the disease area of the review should inform the decision 
of whether to include conference searching as part of the protocol. To answer this 
question more conclusively, a more expansive review of SRs should be conducted 
covering a greater number of SRs and disease areas.
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OBJECTIVES: Health care decision makers are increasingly requesting health eco-
nomic (HE) data, both to support product approval and for marketing purposes. 
Currently, there is limited information available to aid decisions surrounding the 
clinical monitoring of HE endpoints when they are collected as part of a clinical trial. 
It is necessary to understand the current level of monitoring activities surrounding HE 
data and evolve best practices for monitoring such data. METHODS: To better 
understand monitoring activities, a literature review was performed and qualitative 
in-depth interviews were conducted with six clinical research associates (CRA) who 
had experience collecting HE data as part of clinical trials in a range of therapy areas. 
The literature review and interviews focused on understanding current clinical trial 
monitoring practices, monitoring activities speciﬁ c to HE data, the challenges faced 
during monitoring and recommendations for the future. RESULTS: All CRAs inter-
viewed reported working either with patient-reported outcome (PRO) measures—
quality of life questionnaires, patient diaries—and/or health care resource utilization 
data, in different therapy areas. Data monitoring activities in clinical trials can include 
a number of speciﬁ c tasks ranging from full source data veriﬁ cation (SDV) to partial 
SDV to just checking for accuracy, legibility and completeness. The most common 
challenges in monitoring of HE data included incomplete questionnaires, misinterpre-
tation of questionnaire data by the sites, and difﬁ culty in SDV of health care resource 
utilization data by the CRA. Recommendations for the future included optimizing 
methods for documentation of health care resource utilization data, improving patient/
site training in PRO use, and selecting the type of PRO and mode of PRO administra-
tion based on the patient population being examined. CONCLUSIONS: Health eco-
nomic endpoints are increasingly being used in clinical trials, and CRAs are becoming 
familiar with PRO and health care resource utilization data. Monitoring activities for 
HE data vary by the study design and type of data collected. 
CARDIOVASCULAR DISORDERS – Clinical Outcomes Studies
PCV1
ESTIMATION OF STROKE-RELATED ADVERSE EVENTS, HEALTH CARE 
UTILITY AND COST OF PATIENTS WITH NON-VALVULAR ATRIAL 
FIBRILLATION
Wang L1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA; 2STATinMED Research/University of Michigan, 
Ann Arbor, MI, USA
OBJECTIVES: To estimate mortality, health care utility and health care cost burden of 
patients who suffered a stroke during the 180 days after diagnosis of non-valvular atrial 
ﬁ brillation (NVAF) and compare it with patients who did not suffer a stroke. 
METHODS: Based on 2005–2007 U.S. Medicare advantage insurance claim ﬁ les, 
patients aged 65 years and older who had 2 or more primary diagnoses for NVAF within 
30 days of one another were selected. The 180-day follow-up event rates, health care 
facility use and health care cost for patients with a stroke and those without were 
compared. Risk adjustment was done by using the propensity score matching method 
with the ProbChoiceTM algorithm. RESULTS: Out of patients identiﬁ ed with NVAF (n 
= 18,575), 575 suffered a stroke during the 180 days after NVAF diagnosis. 94% (n = 
541) did not have stroke during the baseline period (180 days before NVAF diagnosis). 
Patients were not signiﬁ cantly different in terms of gender, region, and baseline comor-
bid conditions. After risk-adjustment for pre-speciﬁ ed covariates, mortality (7.14% vs. 
2.09% P < 0.0001), outpatient emergency room (ER) visits (79.97% vs. 46.34% P < 
0.0001), acute coronary syndrome (43 vs. 16/100 person years), transient ischemic 
attack (73 vs. 4 /100 person years), major bleeding (85 vs. 4 /100 person years) and 
myocardial infarction (32 vs. 9/100 person years) were all higher for patients who suf-
fered a stroke compared to those who did not. Besides inpatient cost ($24,116 vs. 
$20,828), risk-adjusted outpatient ER costs ($921 vs. $873) were also higher for stroke 
patients. Overall risk-adjusted difference in health care costs is signiﬁ cant ($33,430 vs. 
$16,375 P < 0.0001). CONCLUSIONS: Most of the adverse events analyzed were 
higher for patients who suffered a stroke after NVAF relative to patients who did not. 
Total health care utility and health care cost were also signiﬁ cantly increased.
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OBJECTIVES: To estimate mortality, re-hospitalization and bleeding 180 days after 
a venous thromboembolism (VTE) event in patients following hip fracture surgery and 
to compare the outcomes with patients without VTE. METHODS: Based on 2004–
2006 national Medicare claims, all patients who underwent hip fracture surgery were 
identiﬁ ed. a total of 180 days follow-up event rates for patients who had a VTE event 
during their initial hospitalization were calculated. Events were compared between 
patients who suffered a VTE event and those that did not. Risk adjustment was done 
using propensity score matching (using the ProbChoiceTM algorithm) controlling for 
baseline demographic and clinical characteristics between patients with and without 
VTE. RESULTS: In patients who underwent hip fracture surgery (n = 77,743), 2.23% 
had post-operative VTE events during their initial hospitalization. Almost 72.96% (n 
= 1263) of these patients suffered deep vein thrombosis (DVT), 20.97% (n = 363) had 
a pulmonary embolism (PE), and 6.07% (n = 105) had both DVT and PE. After 
multivariate adjustment for pre-speciﬁ ed covariates, mortality was almost 50% higher 
for patients with VTE compared to those without VTE. Differences in mortality rate 
were more pronounced for PE patients, whom the event was associated with almost 
two-fold. The VTE group was more likely to be re-hospitalized in one year (odds ratio: 
1.18, p = 0.2720). Bleeding was 1.8 times higher (p = 0.0080). CONCLUSIONS: VTE 
events during initial hospitalization for hip fracture surgery increased patients’ mortal-
ity, re-hospitalization and bleeding compared to patients with no VTE events.
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OBJECTIVES: To estimate the economic and clinical burden of patients who used 
warfarin during the 180 days after diagnosis of non-valvular atrial ﬁ brillation (NVAF) 
and compare it with patients who did not use warfarin. METHODS: Based on 
2005–2007 U.S. Medicare advantage insurance claim ﬁ les, patients aged 65 years and 
older who have had 2 or more primary diagnoses for NVAF occurring within 30 days 
of one another were selected. The 180 days follow-up event rates, health care facility 
use and cost were compared. Risk adjustment was done by using the propensity score 
matching method with the ProbChoiceTM algorithm. RESULTS: In patients who 
identiﬁ ed with NVAF (n = 18,575) 12,186 used warfarin during the 180 days after 
NVAF diagnosis and 6,389 used other drugs or did not use any drugs. Patients were 
signiﬁ cantly different in terms of age, gender, comorbid conditions and baseline 
CHADS score. After risk-adjustment for pre-speciﬁ ed covariates, mortality (0.75% vs. 
2.26%), outpatient emergency room (ER) visits (48.79% vs. 53.30%), acute coronary 
syndrome (105 vs. 154 /100 person years), and myocardial infarction (61 vs. 112 /100 
person years) were all lower for patients who had warfarin with non-valvular atrial 
ﬁ brillation. Even though drug cost is higher for the warfarin group ($1,687 vs. 
$1,595), risk-adjusted outpatient ER costs ($756 vs. $861) were lower. Overall risk-
adjusted health care costs did not differ ($12,739 vs. $15,359). CONCLUSIONS: 
Most of the adverse events analyzed were lower for patients who had warfarin after 
non-valvular atrial ﬁ brillation relative to patients who did not. However, the economic 
burden of both groups of patients on the health care system was similar.
